[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613766":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":56,"collaborators":59,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":74,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A (Retrospective)",null,"A retrospective cohort of cases diagnosed between 2010 and 2024, assembled from medical-record data.\n\nTarget enrollment: 1,300-1,500 patients.",[13],"Other: Observational",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B (Prospective)","A prospective cohort of patients newly diagnosed between 2025 and 2030, ensuring ≥5-year follow-up for all survivors.\n\nTarget sample size: 1,000-1,500 cases, estimated from participating centers' annual diagnostic volumes over a 5-year accrual period. The cohort should be multidimensionally representative, including: (i) geographic coverage across North, East, South, Southwest, and Northeast China; (ii) hospital tiers with tertiary (\"Class III Grade A\") institutions as the core and selective inclusion of prefecture-level hospitals; and (iii) economic diversity spanning regions with differing levels of socioeconomic development.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Observational",[9,15],[23],{"name":24,"affiliation":5,"role":25},"Rong Tao, MD","STUDY_CHAIR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","008621-64175590","660103","hkutao@hotmail.com",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"Chuanxu Liu, MD","liuchaunxu@shca.or.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","201200","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51,53,54],{"name":24,"role":28,"phone":52,"phoneExt":10,"email":31},"021-64175590",{"name":33,"role":28,"phone":52,"phoneExt":10,"email":34},{"name":33,"role":55,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Rong Tao","Professor & Chief",[60],{"name":61,"class":6},"The First Affiliated Hospital of Zhengzhou University","100613766","real-world-outcomes-of-peripheral-t-cell-lymphoma-a-multicenter-retrospective-and-prospective-cohort-study-100613766",false,"NCT07270861","Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study","A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma","Inclusion Criteria:\n\n* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).\n* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.\n* Cohort B: Patients newly diagnosed from October 2025 onward.\n* Availability of basic diagnostic and treatment records .\n\nExclusion Criteria:\n\n* Indeterminate diagnosis or missing pathology report.\n* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.\n* Diagnoses of NK\u002FT-cell lymphoma or primary cutaneous T-cell lymphomas.","ALL","18 Years",{"count":72,"type":73},3000,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.",[78],"Peripheral T-Cell Lymphoma",[80,81,82,83,84],"T-cell lymphoma","Retrospective cohort","Prospective cohort","Epidemiology","Biomarkers","2026-03-20",{"date":87,"type":88},"2026-03-24","ACTUAL",{"date":90,"type":88},"2025-11-15",{"date":92,"type":73},"2035-12-31",{"name":5,"class":6},1]